Zydus Cadila is an innovative, global pharmaceutical company who is eager to create healthier communities all around the world. In its attempt to achieve it, it has accomplished a goal announced last Friday 10th of November 2017, by receiving COFEPRIS’ (Federal Commission for the Protection Against Sanitary Risk) regulatory approval to commercialize LipaglynTM (Saroglitazar Magnesium) in Mexico for treatment of Dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
In a previous post named INSIGHTS IN NON-ALCOHOLIC STEATOHEPATITIS (NASH), we already talked about this disease and how important it was to look for an accurate treatment to avoid bigger health issues in the future. That is why Althian is proud to be participating in one of this trials that hopefully, in a future, can lead this molecule (Saroglitazar Magnesium) to achieve a novel therapeutic indication and can help more people to improve their quality of life.